Shopping Cart
Remove All
Your shopping cart is currently empty
IL-17B Protein, Human, Recombinant (hFc) V2 is expressed in HEK293 Cells. The accession number is Q9UHF5.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 μg | $63 | 7-10 days | 7-10 days | |
| 10 μg | $98 | 7-10 days | 7-10 days | |
| 20 μg | $163 | 7-10 days | 7-10 days | |
| 50 μg | $319 | 7-10 days | 7-10 days | |
| 100 μg | $539 | 7-10 days | 7-10 days | |
| 200 μg | $945 | 7-10 days | 7-10 days | |
| 500 μg | $1,990 | 7-10 days | 7-10 days | |
| 1 mg | $3,520 | 7-10 days | 7-10 days |
| Biological Activity | Immobilized Human IL-17B, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-IL-17B Antibody, hFc Tag with the EC50 of 18.0 ng/ml determined by ELISA. |
| Description | IL-17B Protein, Human, Recombinant (hFc) V2 is expressed in HEK293 Cells. The accession number is Q9UHF5. |
| Species | Human |
| Expression System | HEK293 Cells |
| Accession Number | Q9UHF5 |
| Synonyms | ZCYTO7,NIRF,interleukin 17B,IL-20,IL-17B |
| Construction | Gln21-Phe180 |
| Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Molecular Weight | 44.91 kDa (Predicted); 50-60 kDa (Due to glycosylation) |
| Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Stability & Storage | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| Research Background | IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.